{"id":"NCT00391079","sponsor":"GW Pharmaceuticals Ltd","briefTitle":"Sativex Versus Placebo When Added to Existing Treatment for Central Neuropathic Pain in MS","officialTitle":"A Double Blind, Randomised, Placebo Controlled, Parallel Group Study of Sativex When Added to the Existing Treatment Regimen, in the Relief of Central Neuropathic Pain in Subjects With Multiple Sclerosis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-09","primaryCompletion":"2008-04","completion":"2008-09","firstPosted":"2006-10-23","resultsPosted":"2012-07-04","lastUpdate":"2013-06-24"},"enrollment":339,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Multiple Sclerosis"],"interventions":[{"type":"DRUG","name":"Sativex","otherNames":["GW-1000-02"]},{"type":"DRUG","name":"Placebo","otherNames":["GA0034"]}],"arms":[{"label":"A","type":"EXPERIMENTAL"},{"label":"B","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to find out if cannabis-based medicine compared to a dummy medicine (placebo that contains no active ingredient) can help the central neuropathic pain patients experience as a result of multiple sclerosis. This type of pain \"central neuropathic pain\" is described as shooting, stabbing, burning or searing like sensation, which is often worse at night.","primaryOutcome":{"measure":"Change in Mean Pain Due to MS NRS Score","timeFrame":"14 weeks: Baseline - End of Treatment (last 7 days of treatment)","effectByArm":[{"arm":"Sativex","deltaMin":-2.02,"sd":2.15},{"arm":"Placebo","deltaMin":-1.89,"sd":2.33}],"pValues":[{"comp":"OG000 vs OG001","p":"0.468"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":8},"locations":{"siteCount":6,"countries":["Canada"]},"refs":{"pmids":["23180178"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":167},"commonTop":["Dizziness","Fatigue","Dry mouth","Vertigo","Nausea"]}}